NervGen Pharma Corp Cash Flow-to-Debt Ratio
NervGen Pharma Corp cash flow-to-debt ratio. NervGen Pharma Corp (NGEN) has a Cash Flow-to-Debt Ratio of -0.33x as of September 2025, meaning its operating cash flow of CA$-5.32 Million could theoretically repay 0% of its total liabilities (CA$16.02 Million) in one year. See NervGen Pharma Corp free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of NervGen Pharma Corp (2017–2024)
Cash flow-to-debt ratio of NervGen Pharma Corp from 2017 to 2024. Historical debt coverage capacity for NervGen Pharma Corp across 8 annual periods. Also explore NGEN net assets growth trend to track the company's year-over-year net asset growth rate.
NervGen Pharma Corp Cash Flow-to-Debt Ratio by Year (2017–2024)
NervGen Pharma Corp cash flow-to-debt ratio by year from 2017 to 2024. Year-by-year debt coverage analysis for NervGen Pharma Corp. For the full cash flow conversion analysis, see cash flow conversion of NervGen Pharma Corp.
| Year | CF-to-Debt Ratio | Operating CF (CAD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.00x | CA$-16.84 Million | CA$16.91 Million | ▼ -34.4% |
| 2023 | -0.74x | CA$-11.30 Million | CA$15.25 Million | ▲ +56.6% |
| 2022 | -1.71x | CA$-17.78 Million | CA$10.41 Million | ▲ +77.7% |
| 2021 | -7.67x | CA$-8.27 Million | CA$1.08 Million | ▲ +8.2% |
| 2020 | -8.35x | CA$-6.31 Million | CA$755.07K | ▲ +4.7% |
| 2019 | -8.76x | CA$-8.09 Million | CA$923.95K | ▼ -391.1% |
| 2018 | -1.78x | CA$-1.04 Million | CA$583.11K | ▲ +83.7% |
| 2017 | -10.94x | CA$-1.04 Million | CA$95.06K | — |